Investee Company News

December 11, 2017 Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma December 5, 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting December 5, 2017 Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414 November 29, 2017 Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company November 22, 2017 Novan to Present at Piper Jaffray 29th Annual Healthcare Conference November 21, 2017 New Study Proves 2-Minute Cycle with Pulsed Xenon UV Significantly Reduces OR Contamination November 14, 2017 Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit November 13, 2017 Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne November 13, 2017 Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate November 8, 2017 Kymab to present data on its lead immuno-oncology antibody, demonstrating strong potential for inhibiting tumour growth November 8, 2017 Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting November 7, 2017 Novoclem Therapeutics Receives QIDP Status for Its Lead Inhaled Antimicrobial Drug Candidate November 7, 2017 Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution November 6, 2017 Melinta Therapeutics Announces Successful Completion of Merger November 2, 2017 Novoclem Presents Promising New Data At The North America Cystic Fibrosis Conference on November 2, 2017 November 2, 2017 Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting November 1, 2017 Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization October 31, 2017 Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company October 31, 2017 Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting October 30, 2017 Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States October 26, 2017 Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma October 24, 2017 KNOW Bio Strengthens Leadership With The Addition Of Four New Board Members October 24, 2017 Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities October 23, 2017 Viamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017 October 18, 2017 Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide October 13, 2017 Novan Announces Corporate Update Conference Call and Webcast October 10, 2017 Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne October 5, 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat October 4, 2017 New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’ October 4, 2017 Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek